Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ IgG positive 87% Improvement Relative Risk c19hcq.org Goenka et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 962 patients in India Lower IgG positivity with HCQ (p=0.032) Goenka et al., SSRN, doi:10.2139/ssrn.3689618 Favors HCQ Favors control
Seroprevalence of COVID-19 Amongst Health Care Workers in a Tertiary Care Hospital of a Metropolitan City from India
Goenka et al., SSRN, doi:10.2139/ssrn.3689618 (Preprint)
Goenka et al., Seroprevalence of COVID-19 Amongst Health Care Workers in a Tertiary Care Hospital of a Metropolitan City from.., SSRN, doi:10.2139/ssrn.3689618 (Preprint)
Oct 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Study of SARS-CoV-2-IgG antibodies in 1122 health care workers in India finding 87% lower positives for adequate HCQ prophylaxis, 1.3% HCQ versus 12.3% for no HCQ prophylaxis.
Adequate prophylaxis is defined as 400mg 1/wk for >6 weeks.
risk of IgG positive, 87.2% lower, RR 0.13, p = 0.03, treatment 1 of 77 (1.3%), control 115 of 885 (13.0%), NNT 8.6, adjusted per study, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Goenka et al., 24 Oct 2020, retrospective, India, preprint, 11 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: iew ed Seroprevalence of COVID-19 amongst health care workers in a tertiary care hospital of a metropolitan city from India Mahesh Kumar Goenka DM,* Director and head, Institute of Gastrosciences and Liver, Apollo Gleneagles Hospitals, Kolkata, India Shivaraj Afzalpurkar MD, Registrar, Institute of Gastrosciences and Liver, Apollo Gleneagles Hospitals, Kolkata, India Usha Goenka MD, Director and head, Department of Clinical Imaging and Interventional Radiology, Apollo Gleneagles Hospitals, Kolkata, India pe er re v Sudipta Sekhar Das MD, Senior consultant and head, Department of transfusion medicine, Apollo Gleneagles Hospitals, Kolkata, India Mohuya Mukherjee MSc, Clinical data analyst, Apollo Gleneagles Hospitals, Kolkata, India Surabhi Jajodia MD, Consultant, Department of Clinical Imaging and Interventional Radiology, Apollo Gleneagles Hospitals, Kolkata, India Bhavik Bharat Shah DNB, Consultant, Institute of Gastrosciences and Liver, Apollo Gleneagles Hospitals, Kolkata, India Vikram Uttam Patil DNB, Registrar, Institute of Gastrosciences and Liver, Apollo Gleneagles Hospitals, Kolkata, India Gajanan Rodge DNB, Registrar, Institute of Gastrosciences and Liver, Apollo Gleneagles Hospitals, Kolkata, India ot Ujjwayini Khan MD, Consultant, Department of Microbiology, Apollo Gleneagles Hospitals, Kolkata, India *Corresponding tn Syamasis Bandyopadhyay MD, Senior Consultant, Department of Internal Medicine, Apollo Gleneagles Hospitals, Kolkata, India author Pr ep rin Dr. Mahesh Kumar Goenka, Institute of Gastrosciences and Liver, Apollo Gleneagles Hospitals Limited, 58, Canal Circular Road, Kolkata, India Email id- mkgkolkata@gmail.com This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3689618 iew ed Seroprevalence of COVID-19 amongst health care workers in a tertiary care hospital of a metropolitan city from India Abstract Background Seroprevalence studies for COVID-19 evaluate the extent of undetected transmission in a defined community, with special significance among health care workers (HCW) owing to their greater exposure and potential to transmit. pe er re v Methods A total of 1122 HCW (approximately 25% of the employees) of a large tertiary care hospital in India were recruited for this cross-sectional study. COVID PCR-positive HCW were excluded. Based on their risk-assessment, participants were grouped into three categories. A questionnaire was administered and they were tested for SARS-CoV-2-IgG antibodies using the chemiluminescence. ot Findings The overall seroprevalence among workers was 11.94%, which included 19.85% in COVID units, 11.09% in non-COVID units, and 8% in administrative workers (p=0.007). Antibody prevalence was highest in the department of gastroenterology (11.94%), followed by oncology (10.53%), pathology (10.26%), emergency medicine (7.84%) and critical care medicine (7%). Housekeeping staff, food and beverage staff, lab assistants and technicians had higher seroprevalence rate than doctors and nurses (p < 0.0001). HCW with a history of BCG vaccination in childhood and those who received an adequate prophylactic dose of hydroxychloroquine (HCQ) had a lower seroprevalence as compared to those who did not (7.31% vs. 16.8% and 1.30% vs. 11.25% respectively). tn Interpretation BCG vaccination, HCQ prophylaxis, and the job profile influence the seroprevalence rate in HCW. Seroprevalence rate and follow-up evaluation of its..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit